Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism
Launched by UNIVERSITY OF READING · Jan 30, 2024
Trial Information
Current as of June 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether taking 100mg of Vitamin B6 each day can help reduce anxiety and improve sensory sensitivity in adults with autism. The researchers will compare the effects of Vitamin B6 to a placebo (a pill that does not contain the active ingredient) to see if there are any differences in how participants feel and react to sensory experiences.
To be eligible for this study, participants need to be between 18 and 60 years old and have a diagnosis of autism. However, those who are currently taking other Vitamin B6 supplements or certain medications, or have specific health issues like peripheral neuropathy (a nerve condition), will not be able to join. If someone participates, they will either receive the Vitamin B6 or the placebo for a set period and will be monitored for any changes in their anxiety and sensory responses. This trial is currently recruiting participants, so it's a great opportunity for those who meet the criteria and are looking for ways to manage their symptoms.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between the ages of 18 to 60
- • With a diagnosis of autism
- Exclusion Criteria:
- • Taking any supplement that contains more than 2mg of Vitamin B6 or taking GABA agonist drugs
- • Have a medical history of peripheral neuropathy
- • lactose intolerance (placebo tablet is lactose based)
About University Of Reading
The University of Reading is a prestigious research institution in the United Kingdom, renowned for its commitment to advancing knowledge across various disciplines, including health sciences. As a clinical trial sponsor, the university leverages its cutting-edge research facilities and interdisciplinary expertise to conduct innovative studies aimed at improving healthcare outcomes. With a strong emphasis on ethical research practices and collaboration with industry partners, the University of Reading strives to contribute valuable insights to the field of medicine, fostering the development of new treatments and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reading, , United Kingdom
Patients applied
Trial Officials
Dr David T Field, PhD
Principal Investigator
University of Reading
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported